Literature DB >> 12941829

Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma.

Paraskevi A Farazi1, Jonathan Glickman, Shan Jiang, Alice Yu, Karl Lenhard Rudolph, Ronald A DePinho.   

Abstract

Telomere maintenance and telomerase reactivation are near universal features of human hepatocellular carcinoma (HCC), yet the shorter telomeres and highly abnormal cytogenetic profiles of HCC suggest that telomere erosion and dysfunction may be operative during the formative stages of tumorigenesis. Previous studies have established that the cancer-enhancing or suppressing impact of telomere dysfunction is highly dependent on several parameters including cell type, tumor stage, and p53 status. Here, to understand better the pathogenetic role of telomere dysfunction in the initiation and progression in human HCC, we have used three mechanistically distinct liver cancer-prone model systems (urokinase plasminogen activator transgenic mice, carbon tetrachloride exposure, and diethylnistrosamine treatment) in the context of successive generations of telomerase-deficient mice null for the telomerase RNA component, mTERC. Across all of the HCC model systems, telomere dysfunction suppressed both the incidence and growth of HCC lesions, a trend that mirrored the level of intratumoral proliferative arrest and apoptosis. On the histological level, telomere dysfunction was associated with a significant increase in the number of early stage neoplastic lesions and a reciprocal decline in the occurrence of high-grade malignancies. These genetic data in the mouse indicate that telomere dysfunction exerts an opposing role in the initiation versus progression of HCC and provide a framework for understanding the intimate link among chronic liver disease, chromosomal instability, and increased HCC in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941829

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Telomerase inhibitor PinX1 provides a link between TRF1 and telomerase to prevent telomere elongation.

Authors:  Christina Y Soohoo; Rong Shi; Tae Ho Lee; Pengyu Huang; Kun Ping Lu; Xiao Zhen Zhou
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

2.  Hepatocytes with extensive telomere deprotection and fusion remain viable and regenerate liver mass through endoreduplication.

Authors:  Eros Lazzerini Denchi; Giulia Celli; Titia de Lange
Journal:  Genes Dev       Date:  2006-10-01       Impact factor: 11.361

Review 3.  Telomere dysfunction and tumour suppression: the senescence connection.

Authors:  Yibin Deng; Suzanne S Chan; Sandy Chang
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

Review 4.  Chronic hepatitis B in hepatocarcinogenesis.

Authors:  N H Park; I H Song; Y-H Chung
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

Review 5.  Role of alcohol in the development and progression of hepatocellular carcinoma.

Authors:  Iain H McKillop; Laura W Schrum; Kyle J Thompson
Journal:  Hepat Oncol       Date:  2015-11-30

6.  Transient telomere dysfunction induces chromosomal instability and promotes carcinogenesis.

Authors:  Yvonne Begus-Nahrmann; Daniel Hartmann; Johann Kraus; Parisa Eshraghi; Annika Scheffold; Melanie Grieb; Volker Rasche; Peter Schirmacher; Han-Wong Lee; Hans A Kestler; André Lechel; K Lenhard Rudolph
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

7.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

8.  Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Wei Wu; Min Yao; Li-Wei Qiu; Xin-Hua Wu; Xiao-Qin Su; Li Zou; Deng-Bing Yao; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

9.  Distinct dosage requirements for the maintenance of long and short telomeres in mTert heterozygous mice.

Authors:  Natalie Erdmann; Yie Liu; Lea Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 10.  Molecular targeted therapies in hepatocellular carcinoma.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.